AlphAIAlphAI — Financial news for AI agents
timothysykes.comSEP 192 min read$TWST

TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal

Twist Bioscience (TWST) stock rose 7.1% after securing an AI deal with Eli Lilly. The company reported $377M revenue, 52% gross margin, and -31.8% EBIT margin. Analysts highlight its AI-driven drug discovery capabilities but note persistent losses and rich valuation at 24x sales. Technical analysis suggests strong bullish momentum with support at $155.

Original reporting
timothysykes.com
Published Sep 19, 2026, 2:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 3:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal — source image
Source · timothysykes.com
Decision brief

The 30-second read

$TWSTBullishMed
01

Why it matters

The deal is expected to improve Twist's top‑line visibility and may attract further institutional buying, supporting the recent price breakout.

02

Market read

The announcement triggered a 7% intraday rally, making the story highly relevant for short‑term traders.

03

What to watch

Twist's negative profitability and reliance on external funding may limit upside despite the deal.

Relevance 7/10Novelty 7/10Timing: today

Background

Twist Bioscience is a synthetic‑biology company with strong revenue growth but negative earnings. The Eli Lilly TuneLab agreement is presented as a new AI‑driven drug‑discovery collaboration.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience surged 7.1% after announcing an AI-driven deal with Eli Lilly's TuneLab.

Expected impact

upward pressure likely to continue if the partnership yields milestones

Evidence & confidence

The deal validates Twist's AI‑enabled antibody platform and aligns with analyst upgrades, supporting further upside.

Market effects

Sector

Highlights growing AI integration in synthetic biology, potentially lifting peers in biotech tools.

Regional

U.S. biotech sector may see increased investor interest following the partnership.

Global

The collaboration underscores cross‑border AI‑driven drug discovery trends.

Counterpoint

What could challenge this read

If the partnership fails to deliver commercial milestones, Twist could face heightened cash‑burn concerns.

Key entities

  • company
    Twist Bioscience Corporation

    Synthetic‑biology firm issuing the stock ticker TWST.

  • company
    Eli Lilly and Company

    Pharmaceutical giant partnering with Twist on AI drug discovery.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 19
$LLYHighAI 9/10

Inluriyo Plus Verzenio Wins Full FDA Approval for ESR1 Mutated Advanced Breast Cancer After Progression on Endocrine Therapy

The FDA granted full approval to Eli Lilly's imlunestrant (Inluriyo) combined with abemaciclib (Verzenio) for treating ESR1-mutated advanced breast cancer post-endocrine therapy. Approval based on EMBER-3 trial showing median progression-free survival of 11.1 months for the combination vs. 5.5 months for imlunestrant alone in 159 patients. Guardant360 CDx assay approved as companion diagnostic. Common side effects include diarrhea and reduced neutrophil counts.

medicaldaily.com3 min
SEP 19
$TWSTHigh

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

timothysykes.com2 min
SEP 19
$LLYHighAI 9/10

Health: US FDA approves Lilly's breast cancer drug combo

The US FDA approved Eli Lilly's Inluriyo-Verzenio combo for treating advanced breast cancer with ESR1 mutations. The approval follows a study showing 11.1 months of progression-free survival vs. 5.5 months with Inluriyo alone. The combo is for ER-positive, HER2-negative patients who progressed after hormone therapy.

gdnonline.com2 min
SEP 19
$LLYMedAI 8/10

Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge

Eli Lilly (LLY) maintains a strong position in the weight-loss drug market. Its oral GLP-1 drug, Foundayo, is gaining on Novo Nordisk's (NVO) Wegovy pill, with the prescription gap narrowing. Foundayo's convenience may drive adoption, though patient switching could slow progress. Additionally, Eli Lilly's selpercatinib tablets were approved in China, expanding its product pipeline. Analysts expect the weight-loss drug market to reach $100 billion by 2030.

nai500.com2 min
SEP 19
$LLYHighAI 9/10

FDA Grants Full Approval To Lilly's Inluriyo Plus Verzenio For ESR1-Mutated Breast Cancer

Eli Lilly (LLY) received FDA full approval for Inluriyo in combination with Verzenio to treat ESR1-mutated breast cancer. The treatment is for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. LLY shares closed at $1,152.93 on Friday. Inluriyo is also in Phase 3 trials for early-stage breast cancer, with results expected in 2027.

rttnews.com1 min
SEP 19
$LLYHighAI 9/10

FDA Approves Inluriyo-Verzenio for ESR1-Mutated Breast Cancer

FDA approved Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. The approval is based on EMBER-3 trial data showing improved progression-free survival in a subgroup. Eli Lilly, which makes both drugs, announced the decision. Guardant360 CDx is the approved companion diagnostic.

findarticles.com2 min